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Cardiac toxicity following the administration of chemotherapeutic agents is well documented. Vinca 
alkaloids, as well as high-dose cyclophosphamide, have been associated with myocardial ischemia. The 
present report describes a case of acute myocardial infarction occurring in a patient with no antecedent 
cardiac history who received both vincristine and conventional chemotherapeutic doses of cyclophos- 
phamide for the treatment of chronic lymphocytic leukemia. Physicians should possess a heightened 
awareness of this potentially serious complication. 
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Introduction 
Cardiac toxicity following the administration of anti- 
neoplastic agents is well documented (1). Cardiomy- 
opathy, angina pectoris, myocardial infarction, 
arrhythmias, heart block, myocarditis and pericardi- 
tis have all been reported following chemotherapy. 
Although the best-described cardiac toxicity ascribed 
to antineoplastic agents is with anthracyclines, 
adverse cardiac events have been reported with other 
agents. 
The present case report describes a case of acute 
myocardial infarction occurring in a patient with no 
antecedent cardiac history who received both cyclo- 
phosphamide and vincristine intravenously for the 
treatment of chronic lymphocytic leukemia. 
Case Report 
A 67-year-old man without a previous history of 
heart disease was admitted to the hospital after a 
complete blood count was suggestive of chronic lym- 
phocytic leukemia (CLL). He claimed to have been in 
excellent health until 1 month prior to admission 
when he developed fatigue, mild anorexia and a 10 
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pound weight loss. He denied fevers, chills, night 
sweats, chest pains, shortness of breath or a history of 
diabetes or hypertension. 
Prior to admission, he had been using acetami- 
nophen as needed for foot pain. He was unaware of 
his serum cholesterol level. He had an 80 pack-year 
smoking history, but had not smoked cigarettes for 
15 yr. He was employed as a carpenter, and was 
extremely active at work. Family history was not 
significant for either leukemia or premature heart 
disease. 
On physical examination, he was noted to be 
slightly pale. He was 66 inches tall and weighed 147 
pounds. Vital signs were unremarkable except for a 
pulse of 102 beats min ‘. No adenopathy was appre- 
ciated. The cardiac examination revealed a regular 
tachycardia without murmurs, rubs or gallops. The 
patient’s lungs were clear to auscultation, and no 
hepatomegaly or splenomegaly were palpated. 
Results of a complete blood count revealed a 
hemoglobin of 8 g dl - ‘, and a white blood count of 
300 000 mm- 3 with 88% lymphocytes, 9% blasts 
and 3% prolymphocytes. The platelet count was 
180 000 mmm3. Routine chemistries including elec- 
trolytes, blood urea nitrogen and creatinine were 
unremarkable. Serum aspartate aminotransferase was 
26 U 1 - ‘, alanine aminotransferase 18 1 - r, alkaline 
phosphatase 82 U 1 - ‘, total bilirubin 0.3 mg dl- ’ 
and direct bilirubin 0.1 mg dl - ‘. 
On the second hospital day, he was treated with a 
chemotherapy regimen including 1300 mg of cyclo- 
phosphamide (738 mg m - 2 based on his body surface 
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FIG. 1. Electrocardiogram of the patient (a) prior to receiving chemotherapy and (b) with chest pain after 
receiving chemotherapy. 
area of 1.76 m - 2, over 15 min and 2 mg of vincristine 
given intravenously. Approximately 8 h after the 
initiation of the chemotherapy, the patient developed 
prolonged retrosternal chest pressure radiating down 
both arms, only minimally relieved by nitroglycerin 
and morphine sulfate. ST segment elevation was 
noted by ECG in leads II, III and a VF, and in leads 
V3-V6. In addition, the electrical voltage was 
deceased when compared to the admission ECG 
(Fig. 1). Creatine phosphokinase (CPK) rose from 
82 U 1 - ’ with an MB fraction of 2 ng ml - ’ at 
the inception of chest pain to 2049 U 1 - ’ with an 
MB of 274 ng ml - ’ 16 h later (normal values: CPK 
O-180 U 1 - ‘, MB less than 5 ng ml - ‘). An echo- 
cardiogram performed 2 days after the chest pain 
episode demonstrated apical dyskinesis with a mural 
thrombus. The left ventricular ejection fraction was 
estimated to be between 35 and 40%, and a small 
non-hemodynamically significant posterior pericar- 
dial effusion was observed. A dipyridamole cardiac 
positron emission scan revealed severe fixed infralat- 
era1 and apical perfusion defects. There was no evi- 
dence of inducible myocardial ischemia. The patient 
was eventually discharged home and has remained 
without chest pain. 
Discussion 
Cyclophosphamide and vincristine are widely utilized 
chemotherapeutic agents, and each has been associ- 
ated with cardiotoxicity (2,lO). Several reports have 
emerged in the literature implicating vinca alkaloids 
and myocardial ischemia. Chest pain, T-wave inver- 
sions on ECG, congestive heart failure without a rise 
of cardiac enzymes [suggesting reversible cardiac 
ischemia (2)] as well as complicated myocardial 
infarction have been attributed to vinca alkaloids. In 
at least two of the cases of completed infarction, 
coronary angiography revealed normal epicardial 
vessels (3,4). 
High-dose cyclophosphamide, frequently employed 
in combination with autologous bone marrow trans- 
plantation, has been noted to cause myocarditis, 
pericardial effusion, reduction in electrocardiographic 
voltage, congestive heart failure, arrhythmias, non- 
specific ST-T wave changes, heart block and myocar- 
dial necrosis (S-7). Autopsy reports from fatal cases 
have revealed diffuse myocardial edema, ischemic 
degeneration, focal cardiac necrosis with hemorrhage, 
fibrin deposition and vascular endothelial damage 
(6-8). 
Conventional chemotherapeutic doses of cyclo- 
phosphamide have been reported to cause toxicity 
that resembles myocardial ischemia with chest pain 
and abnormal ECG, but without cardiac enzyme 
elevation (9,lO). One patient who experienced chest 
pain with ECG abnormalities subsequently under- 
went dipyriadmole-thallium imaging which revealed 
no reversible perfusion abnormalities (10). 
The authors are unaware of any prior report of a 
myocardial infarction in a patient receiving a conven- 
tional dose of cyclophosphamide. It is unclear 
whether or not the ST segment elevation, loss of 
electrocardiographic voltage and myocardial enzyme 
elevation was caused by coincident coronary artery 
disease, vincristine or cyclophosphamide alone, or the 
potentiation of one chemotherapeutic agent’s cardio- 
toxicity by the other. This patient’s complete absence 
of chest pain while performing heavy manual labor 
prior to admission, and the striking temporal rela- 
tionship between receiving the antineoplastic agents 
and manifesting chest pain, mitigate against him 
exhibiting coincidental coronary artery disease and 
myocardial infarction. 
Although there have been reports of vinca alkaloid 
as well as high-dose cyclophosphamide induced 
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cardiac toxicity, it is possible that the combination of 
these two agents, even with conventional chemothera- 
peutic doses of cyclophosphamide, pose a significant 
threat to patients. Although the rarity of this syn- 
drome should not dictate that physicians administer 
these agents in a monitored setting, the authors feel 
it would be prudent to possess a heightened aware- 
ness of this serious and potentially life-threatening 
complication. 
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